Imfinzi Achieves European Milestone: First Immunotherapy to Improve Survival in Early Gastric Cancer

AstraZeneca has received European Commission approval for Imfinzi (durvalumab) in combination with FLOT chemotherapy, a landmark achievement representing the first immunotherapy-based regimen to demonstrate survival benefits in early-stage gastric and…

Continue Reading Imfinzi Achieves European Milestone: First Immunotherapy to Improve Survival in Early Gastric Cancer
ICYMI: Trial Begins to Evaluate Savolitinib and IMFINZI for Renal Cell Carcinoma
Photo by Robina Weermeijer on Unsplash

ICYMI: Trial Begins to Evaluate Savolitinib and IMFINZI for Renal Cell Carcinoma

According to a news release, researchers from biopharmaceutical company HUTCHMED and pharmaceutical company AstraZeneca launched, at the onset of November 2021, the Phase 3 SAMETA clinical trial. During the trial,…

Continue Reading ICYMI: Trial Begins to Evaluate Savolitinib and IMFINZI for Renal Cell Carcinoma